Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow https://t.co/FeYrdlwQsA
Links:
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneou…
http://ow.ly/QHHc50LyKfB
13-11-2022